—According to researchers in Germany, the presence of additional cytogenetic or molecular markers included in current risk stratification systems, rather than the presence or absence of a trisomy 8, ...
Researchers used an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS) to identify inflammatory proteins with newly diagnosed AML.
Aston Martin share price has come under pressure since its initial public offering as the company has continued burning cash.
Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy The therapeutic arsenal for the management of AML has expanded ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback